ERBB2 and breast cancer: Our findings are in line with recently published results by Francois et al. showing a change in treatment approach due to staging by FDG-PET/CT for 22 % of the patients with stage IIA (T2N0) HER2+BC, compared to only 10 % for the patients with stage I HER2+ BC [23].